Is Klotho Neurosciences, Inc. (KLTO) a Buy, Sell, or Hold?
NASDAQ : KLTO
Klotho Neurosciences, Inc.
$0.381 USD
-$0.03 (-7.1%)
- Volume
- 95K
- Average Volume
- 3.23M
- Market Capitalization
- $20.08M
- P/E Ratio
- -1.13
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $3.91
- Year Low
- $0.11
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $19.74
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Joseph A. Sinkule |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KLTO |
| CUSIP | 49876K103 |
| CIK | 0001907223 |
| Web | https://klothoneuro.com |
| Phone | 833 931 6330 |
| Currency | USD |
| Employees | 3 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 19.74 |
| Quick Ratio | 19.74 |
| Cash Ratio | 18.06 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -0.10 |
| Price / Cash Flow | -2.09 |
| Price / Book | 0.69 |
Price Target and Rating
| Average Stock Price Forecast | |
| High Stock Price Forecast | |
| Low Stock Price Forecast | |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$0.22 |
| Trailing P/E Ratio | -1.13 |
| PEG Ratio | 0.08 |
| P/E Growth | 0.08 |
| Net Income | -$10.55M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -108.82% |
| Return on Assets | -37.12% |
Financials Score
| AltmanZ Score | 0.00 |
| Piotroski Score | 2.00 |
| Working Capital | 10.38M |
| Total Assets | 59.74M |
| Ebit | -15.38M |
| Market Cap | 20.08M |
| Total Liabilities | 8.27M |
Poll Results
About Klotho Neurosciences, Inc. (NASDAQ:KLTO) Stock
Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska. ...
Frequently Asked Questions
-
What is the current Klotho Neurosciences, Inc. (KLTO) stock price?
-
Klotho Neurosciences, Inc.(NASDAQ:KLTO) stock price is $0.381 in the last trading session. During the trading session, KLTO stock reached the peak price of $3.91 while $0.114 was the lowest point it dropped to. The percentage change in KLTO stock occurred in the recent session was --7.1% while the dollar amount for the price change in KLTO stock was -$0.03.
-
KLTO's industry and sector of operation?
-
The NASDAQ listed KLTO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KLTO?
-
Joseph Sinkule | Founder, Chief Executive Officer, Chairman of the Board & Secretary
Shalom Z. Hirschman | Medical Advisor & Director
Jeffrey LeBlanc | Chief Financial Officer
Peter J. Moriarty | Chief Business Officer
Miguel Chillon Rodriguez | Chief Scientific Officer & Consultant -
How many employees does KLTO have?
-
Number of KLTO employees currently stands at 3. KLTO operates from 13576 Walnut Street, Omaha, NE 68144, US.
-
Link for KLTO official website?
-
Official Website of KLTO is: https://klothoneuro.com
-
How do I contact KLTO?
-
KLTO could be contacted at phone #833 931 6330 and can also be accessed through its website. KLTO operates from 13576 Walnut Street, Omaha, NE 68144, US.
-
How many shares of KLTO are traded daily?
-
The average number of KLTO shares traded daily for last 3 months was 3.23M.
-
What is the market cap of KLTO currently?
-
The market value of KLTO currently stands at $20.08M with its latest stock price at $0.381